Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML (N Engl J Med 2019;381:1728-1740). The article contained errors in the numbers of patients receiving previous FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy. In the first paragraph of the Patients subsection of Results (page 1731), the sentence beginning "Most patients" should have read, "Most patients (83.8%) had received previous induction therapy with anthracyclines but not FLT3 inhibitors (86.8%); 23 patients (6.2%) had received the FLT3 inhibitor midostaurin," rather than, ". . . but not FLT3 inhibitors (87.6%); 21 patients (5.7%) had received the FLT3 inhibitor midostaurin." In the final sentence of this subsection, the parenthetical value given for withdrawal by the patient should have been . . .
File in questo prodotto:
Non ci sono file associati a questo prodotto.